188 related articles for article (PubMed ID: 15452186)
1. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
[TBL] [Abstract][Full Text] [Related]
2. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.
Karcher J; Dyckhoff G; Beckhove P; Reisser C; Brysch M; Ziouta Y; Helmke BH; Weidauer H; Schirrmacher V; Herold-Mende C
Cancer Res; 2004 Nov; 64(21):8057-61. PubMed ID: 15520216
[TBL] [Abstract][Full Text] [Related]
3. Toward a glioblastoma vaccine: promise and potential pitfalls.
Fine HA
J Clin Oncol; 2004 Nov; 22(21):4240-3. PubMed ID: 15452184
[No Abstract] [Full Text] [Related]
4. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients.
Ishikawa E; Tsuboi K; Yamamoto T; Muroi A; Takano S; Enomoto T; Matsumura A; Ohno T
Cancer Sci; 2007 Aug; 98(8):1226-33. PubMed ID: 17517052
[TBL] [Abstract][Full Text] [Related]
6. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
Wheeler CJ; Das A; Liu G; Yu JS; Black KL
Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
[TBL] [Abstract][Full Text] [Related]
7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
8. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
Herold-Mende C; Karcher J; Dyckhoff G; Schirrmacher V
Adv Otorhinolaryngol; 2005; 62():173-83. PubMed ID: 15608427
[TBL] [Abstract][Full Text] [Related]
9. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
[TBL] [Abstract][Full Text] [Related]
12. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
14. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z
Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820
[TBL] [Abstract][Full Text] [Related]
16. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
19. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
